#United States #New York #John Chiminski #CD&R #Catalent

John Chiminski's New Role at CD&R

In a strategic move that underscores CD&R's commitment to enhancing its healthcare investment portfolio, John Chiminski, the former Chair and Chief Executive Officer of Catalent, Inc., has been appointed as an Operating Advisor. John's extensive background in the pharmaceutical and healthcare sectors will undoubtedly contribute to the firm's growth and value-creation initiatives, specifically within their healthcare investment vertical.

A Legacy of Leadership

John's professional journey spans over three decades, during which he has established himself as a formidable leader in the healthcare space. From 2009 to 2015, he served as the Chief Executive Officer of Catalent, followed by a combination of roles that included both Chair and CEO from 2016 to 2022, and Executive Chair until June 2023. During this period, he was instrumental in transforming Catalent into one of the premier contract development and manufacturing organizations globally.

Under his leadership, Catalent not only navigated its initial public offering in 2014 but also transitioned into a fully independent public entity. The numbers speak volumes about John's success; Catalent experienced a compound annual growth rate (CAGR) of 8% and saw its enterprise value swell to a staggering $18.5 billion by 2024, prior to its acquisition by Novo Holdings for $16.5 billion.

Prior to his tenure at Catalent, John gained invaluable experience at GE Healthcare, where he held senior positions for over twenty years. His roles varied from engineering to operations and included serving as President and CEO of GE Medical Diagnostics. His wealth of experience positions him as a knowledgeable asset who understands the intricacies of both management and operational excellence.

CD&R's Vision for Healthcare Investment

CD&R has made it clear that they seek to build and strengthen businesses that can lead in the healthcare domain. Sarah Kim, a partner at CD&R, emphasized the importance of having John onboard, citing that his industry knowledge, extensive network, and leadership experience would be the perfect fit as they align their investment strategies with innovative healthcare solutions.

As an Operating Advisor, John will play a crucial role in identifying investment opportunities that promise to foster growth in the healthcare sector. He expressed his enthusiasm for collaborating closely with CDR's management to facilitate the emergence and development of healthcare firms aiming to achieve global leadership. His belief in long-term partnerships and sustainable growth aligns perfectly with the ethos of CD&R.

A Continuing Impact on the Healthcare Industry

In addition to his new role at CD&R, John continues to serve as a board member for QuidelOrtho and Radiology Partners. He is also recognized for his advisory roles at Bourne Partners and contributes to the SCW.AI Advisory Board and the Purdue Engineering Advisory Council. John's academic background includes a bachelor’s degree from Michigan State University and both a master’s degree in electrical engineering and an MBA from prestigious institutions, showcasing his commitment to both education and excellence in business.

The future holds exciting prospects for CD&R with John's expertise steering its healthcare investments. As the firm seeks to create meaningful partnerships that cultivate innovation and resilience, the combination of his leadership experience and sector-specific knowledge will be pivotal as they venture into the next phase of growth and strategic investment in healthcare services. CD&R's mission remains steadfast in partnering with management teams to build robust businesses that not only generate returns for investors but also contribute positively to societal wellbeing.

In a market that is constantly evolving, leadership figures like John Chiminski are essential in navigating the complexities of healthcare investment, ensuring sustainable progress in a field that directly impacts communities globally.

Conclusion

As we anticipate the changes that John's involvement will bring to CD&R, the focus on healthcare investments reaffirms the firm's strategic vision. His arrival is a promising chapter for both CD&R and the healthcare sector as a whole. With a leader of John's caliber, CD&R is better equipped to tackle emerging challenges and unlock new opportunities in the healthcare market.